Experimental Antibody Shows Durable Hair Regrowth in Severe Alopecia Areata Trial

Q32 Bio has reported encouraging new data for bempikibart, an experimental antibody being developed for severe alopecia areata, the autoimmune condition in which the immune system attacks hair follicles and causes patchy or complete hair loss. The company announced 36-week results on July 13, 2026, from Part B of its Phase 2a SIGNAL-AA trial. The study enrolled 33 adults with severe or very severe alopecia areata, including a number of participants who had already tried and failed JAK inhibitors, the class of drugs currently approved for this condition.

By week 36, participants on bempikibart saw an average 35.3 percent reduction in their SALT score, a standard measure of how much of the scalp is affected by hair loss, in the modified intent-to-treat population. Roughly 40 percent of patients achieved at least a 20 percent improvement in SALT score, and 44 percent reached at least a 30 to 50 percent improvement. Perhaps most notable to patients and clinicians, the company reported early signs that some responses held up even after people stopped taking the drug, including one patient who regrew a full head of hair.

Bempikibart works differently than the JAK inhibitors already on the market. It is a fully human antibody that blocks two separate signaling pathways, interleukin-7 (IL-7) and thymic stromal lymphopoietin (TSLP), both of which appear to push T cells to mistakenly attack hair follicles. Because it targets a different part of the immune pathway, researchers hope it could work for patients who do not respond well to JAK inhibitors, or offer another option for patients who want to avoid the class's known side effects.

The trial also tracked safety and immunogenicity. Q32 Bio reported that bempikibart showed a favorable pharmacokinetic and pharmacodynamic profile in Part B, with negligible anti-drug antibody formation, a reassuring sign for a biologic drug meant to be used over the long term.

Alopecia areata affects millions of people worldwide and can range from small bald patches to complete loss of scalp and body hair. While it is not physically dangerous, it can take a significant emotional and social toll, and treatment options have been limited until the recent arrival of JAK inhibitors. A second, mechanistically distinct option like bempikibart could give patients and doctors more room to individualize treatment.

Q32 Bio said it is targeting the first half of 2027 to begin a registration-directed program for bempikibart, meaning a pivotal trial intended to support an eventual FDA application. That timeline puts any approval years away, and the current results come from a relatively small trial rather than a large randomized study, so the findings will need to be confirmed in bigger trials. Still, the durability signal after stopping treatment is the kind of result that tends to catch the field's attention, since most current alopecia areata therapies require continuous use to maintain results.